Verona_Pharma_Dark_medium.jpg
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
June 09, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Host KOL Event on June 16, 2022
June 06, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at Jefferies Healthcare Conference
May 25, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
May 09, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces May 2022 Investor Conference Participation
May 04, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022: ...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 03, 2022 02:00 ET | Verona Pharma plc
Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022 James Brady joined the Board as Non-Executive Director Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
April 19, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
James Brady Joins Verona Pharma as Non-Executive Director
March 14, 2022 03:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 03, 2022 02:00 ET | Verona Pharma plc
Phase 3 ENHANCE program on track to report top-line COPD data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- Verona...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
February 17, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...